ULBPs, Novel MHC Class I–Related Molecules, Bind to CMV Glycoprotein UL16 and Stimulate NK Cytotoxicity through the NKG2D Receptor

David Cosman(IDEX Corporation (United States)), N. Jan Chalupny(IDEX Corporation (United States)), Marek Kubin(Amgen (United States)), Wilson Chin(IDEX Corporation (United States)), Jürgen Müllberg(IDEX Corporation (United States)), William C. Fanslow(Laboratoire d'Innovation Thérapeutique), Claire L. Sutherland(IDEX Corporation (United States)), Richard Armitage(Amgen (United States))
Immunity
February 1, 2001
Cited by 1,208


Related Papers